Paclitaxel modifies the accumulation of tumor-diagnostic tracers in different ways in P-glycoprotein-positive and negative cancer cells

European Journal of Pharmaceutical Sciences

Volumn 28, Issue 3, 2006, Pages 249-256

  Krasznai, Zoárd Tibor ^a   Péli Szabó, Judit ^b   Németh, Eniko ^a   Balkay, László ^a   Szabó, Gábor ^a   Goda, Katalin ^a   Galuska, László ^a   Trón, Lajos ^a,b   Major, Tamás ^a   Hernádi, Zoltán ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

11C choline; 18FDG; 99mTc MIBI; MDR; Paclitaxel

Indexed keywords

CHOLINE C 11; DAUNORUBICIN; FLUORODEOXYGLUCOSE F 18; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PACLITAXEL; TRACER; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG POTENTIATION; DRUG UPTAKE; FLOW CYTOMETRY; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BINDING SITES; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FLUORODEOXYGLUCOSE F18; HUMANS; KINETICS; P-GLYCOPROTEIN; PACLITAXEL; PROTEIN BINDING; RADIOACTIVE TRACERS; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI;

EID: 33646795688     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2006.02.006     Document Type: Article

References (43)

1. Alvarez M., Paull K., Monks A., Hose C., Lee J.S., Weinstein J., Grever M., Bates S., and Fojo T. Generation of a drug resistance profile by quantitation of MDR-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J. Clin. Invest. 95 (1995) 2205-2214
2. Bagwell C.B., Mayo S.W., Whetstone S.D., Hithcox S.A., Baker D.R., Herbert D.J., Weaver D.L., Jones M.A., and Lovett E.J. DNA histogram debris theory and compensation. Cytometry 12 (1991) 107-118
3. 99mTc-Sestamibi in vitro. Anticancer Res. 17 (1997) 1833-1840
4. Borst P., and Elferink R.O. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 71 (2002) 537-592
5. Choi J., and Li X. The effect of verapamil on the pharmacokinetics of paclitaxel in rats. Eur. J. Pharm. Sci. 24 (2005) 95-100
6. Druley T.E., Stein W.D., and Roninson I.B. Analysis of MDR1 P-glycoprotein conformational changes in permeabilized cells using differential immunoreactivity. Biochemistry 40 (2001) 4312-4322
7. Ferlini C., Raspaglio G., Mozzetti S., Distefano M., Filippetti F., Martinelli E., Ferrandina G., Gallo D., Ranelletti F.O., and Scambia G. Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol. Pharmacol. 64 (2003) 51-58
8. Glavinas H., Krajcsi P., Cserepes J., and Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr. Drug Deliv. 1 (2004) 27-42
9. Goda K., Balkay L., Márián T., Trón L., Aszalós A., and Szabó Jr. G. Intracellular pH does not affect drug extrusion by P-glycoprotein. J. Photochem. Photobiol. B: Biol. 34 (1996) 177-182
10. Gregory R.E., and DeLisa A.F. Paclitaxel: a new antineoplastic agent for refractory ovarian cancer. Clin. Pharm. 12 (1993) 401-415
11. 18F)-Fluoro-2-Deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J. Nucl. Med. 27 (1986) 235-238
12. Holmes F.A., Walters R.S., Theriault R.L., Forman A.D., Newton L.K., Raber M.N., Buzdar A.U., Frye D.K., and Hortobagy G.N. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst. 83 (1991) 1797-1805
13. Horowitz N.S., Hua J., Gibbs R.K., Muth D.G., and Herzog T.J. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecol. Oncol. 94 (2004) 67-73
14. Horwitz S.B. Mechanism of action of taxol. Trends Pharmacol. Sci. 13 (1992) 134-136
15. Jordan M.A., Toso R., Thrower D., and Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentration. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 9552-9556
16. 99mTc-tetrofosmin uptake in MRP-expressing breast cancer cells under hypoxic conditions is independent of MRP function. Eur. J. Nucl. Med. Mol. Imag. 30 (2003) 1529-1531
17. Kostakoglu L., Kiratli P., Ruacan S., Hayran M., Emri S., Ergün E.L., and Bekdik C.F. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. J. Nucl. Med. 39 (1998) 228-234
18. Krasznai Z.T., Friedlander E., Nagy A., Szabó G., Vereb G., Goda K., and Hernádi Z. Quantitative and functional assay of MDR1/P170-mediated MDR in ascites cells of patients with ovarian cancer. Anticancer Res. 25 (2005) 1187-1192
19. Krishna R., and Mayer L.D. Multidrug resistance (MDR) in cancer. Mechanism, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11 (2000) 265-283
20. Loo T.W., Barlett M.C., and Clarke D.M. Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein: direct evidence for the substrate-induced fit mechanism for drug binding. J. Biol. Chem. 278 (2003) 13603-13606
21. Louie K.G., Hamilton T.C., Winkler M.A., Behrens B.C., Tsuruo T., Klecker R.W., Mchoy W.M., Grotzinger K.R., Meyers C.E., Young R.C., and Ozols R.F. Adriamycin accumulation and metabolism in adriamycin-sensitive and -resistant human ovarian cancer cell lines. Biochem. Pharmacol. 35 (1986) 467-472
22. Mankoff D.A., and Bellon J.R. Positron-emission tomographic imaging of cancer: glucose metabolism and beyond. Semin. Radiat. Oncol. 11 (2001) 16-27
23. Márián T., Szabó G., Goda K., Nagy H., Szincsák N., Juhász I., Galuska L., Balkay L., Mikecz P., Trón L., and Krasznai Z. In vivo and in vitro multitracer analyses of P-glycoprotein expression related multidrug resistance. Eur. J. Nucl. Med. Mol. Imag. 30 (2003) 1147-1154
24. 99mTc]-hexakis-2-methoxyisobutyl isonitrile in tumour cells and its modulation by lipophilic P-glycoprotein ligands. Eur. J. Pharm. Sci. 25 2/3 (2005) 201-209
25. 18F]2-fluoro-2-deoxy-d-glucose, daunorubucin and rhodamine123 in multidrug-resistant and sensitive cells. Eur. J. Pharm. Sci. 24 5 (2005) 495-501
26. Murphy W.K., Fossella F.V., Winn R.J., Shin D.M., Hynes H.E., Gross H.M., Davilla E., Leimert J., Dhingra H., Raber M.N., Krakoff I.H., and Hong W.K. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 85 (1993) 384-388
27. Nadari S., Carruthers A., and Melchior D.L. Modulation of red blood cell sugar transport by lyso-lipid. Biochim. Biophys. Acta 985 (1989) 173-181
28. Pajeva I., Todorov D.K., and Seydel J. Membrane effects of the antitumor drugs doxorubicin and thaliblastine: comparison to multidrug resistance modulators verapamil and trans-flupentixol. Eur. J. Pharm. Sci. 21 (2004) 243-250
29. 11C]choline. J. Label. Comp. Rad. 43 (2000) 195-203
30. Pauwels E.K.J., McCready V.R., Stoot J.H.M.B., and van Deurzen D.F.P. The mechanism of accumulation of tumour-localising radiopharmaceuticals. Eur. J. Nucl. Med. 25 (1998) 277-305
31. Piwnica-Worms D., Rao V., Kronauge J., and Croop J. Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation. Biochemistry 34 (1995) 12210-12220
32. 11C]choline; implications for in vivo imaging with positron emission tomography. Eur. J. Nucl. Med. 27 (2000) 25-32
33. Sarkadi B., Price E.M., Boucher R.C., Germann U.A., and Scarborough G.A. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J. Biol. Chem. 267 (1992) 854-4858
34. Shapiro A.B., Fox K., Lam P., and Ling V. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur. J. Biochem. 259 (1999) 841-850
35. Shin C., Hsu W., Huang W., Wang J., Ho S., and Kao A. Usefulness of chest single photon emission computed tomography with technetium-99m methoxyisobutylisonitrile to predict taxol based chemotherapy response in advanced non-small cell lung cancer. Cancer Lett. 199 (2003) 99-105
36. 2+ antagonists on multidrug resistance. MDR1-mediated transport and MDR1 mRNS expression. Eur. J. Pharm. Sci. 16 (2002) 159-165
37. Tan B., Piwnica-Worms D., and Ratner L. Multidrug resistance transporters and modulation. Curr. Opin. Oncol. 12 (2000) 450-458
38. 18F]fluoro-d-glucose-positron emission tomography. Mol. Imag. Biol. 6 (2004) 172-179
39. 18F-FDG PET. J. Nucl. Med. 44 (2003) 1051-1056
40. Varma M.V.S., and Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: Effect on solubility and permeability in vitro, in situ and in vivo. Eur. J. Pharm. Sci. 25 (2005) 445-453
41. Wahl L.R. Targeting glucose transporters for tumor imaging: "sweet" idea, "sour" result. J. Nucl. Med. 37 (1996) 1038-1041
42. Wiles M.E., Dykens J.A., and Wright C.D. Regulation of plymorphonuclear leukocyte membrane fluidity: effect of cytoskeletal modification. J. Leuk. Biol. 56 (1994) 192-199
43. Yusuf R.Z., Duan Z., Lamendola D.E., Penson R.T., and Seiden M.V. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr. Cancer Drug Targets 3 (2003) 1-19